Before you sell to, join or invest in CoRegen, Inc.
MentionFox check on CoRegen, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/coregen-inc-form-d-25000001
Check CoRegen, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about CoRegen, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
CoRegen, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-22.
CoRegen, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 22, 2025. The filing reports $62.64M sold. Its industry group is Biotechnology. It names Steve Gorlin (President of the Issuer), David Lonard, PhD (Chief Science Officer of the Issuer), John Thomas, Jr. (Chief Financial Officer and Secretary of Issuer) (SEC Form D, May 22, 2025).
Is this your company?
Sell to companies like CoRegen, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns CoRegen, Inc.
Free to see. No signup.
More on the people and the money behind CoRegen, Inc., from the filings we hold.
Biotechnology raises by companies based in Colorado, filed within 90 days of this one, largest first.
Get an email when CoRegen, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when CoRegen, Inc. raises, hires or launches. No email unless you switch it on.
Watch CoRegen, Inc. →Get the full cited report on CoRegen, Inc.
What the filing shows about CoRegen, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CoRegen, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives CoRegen, Inc.'s address as 600 E Hopkins Ave, Ste 304, Aspen, CO 81611.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for CoRegen, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
CoRegen, Inc. is a registered filer with the SEC (CIK 2012886) and has filed since 2024-02-22. 6 filings are on record, the latest on 2026-02-26.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
CoRegen, Inc.'s Form D of 2025-05-22 names Steve Gorlin, David Lonard, PhD, John Thomas, Jr. and 7 more as its officers, directors or promoters.
Its new offerings report $134.26M sold across 6 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer, Director.
Steve Gorlin is named as President of the Issuer on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
David Lonard, PhD is named as Chief Science Officer of the Issuer on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
John Thomas, Jr. is named as Chief Financial Officer and Secretary of Issuer on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
Bert O'Malley is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer, Director.
Clifford Dasco, M.D. is named as Chief Medical Officer of the Issuer on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
Edward Benz, Jr. is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
Lee Fleisher, M.D. is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
Suneet Varma is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
William Haseltine, PhD. is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
Jonathan Simons is named as Director on the Form D that CoRegen, Inc. filed with the SEC on 22 May 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-05-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about CoRegen, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CoRegen, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CoRegen, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CoRegen, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind CoRegen, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for CoRegen, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/coregen-inc-form-d-25000001